US Patent

US11266799 — In-line nasal delivery device

Formulation · Assigned to Impel Neuropharma Inc · Expires 2036-11-05 · 10y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects an in-line nasal delivery device for a compound, specifically designed to hold a vial of the compound and a propellant source.

USPTO Abstract

A delivery device for a compound including: a housing, vial holding a compound; and a source of propellant, wherein the housing provides an inlet and an outlet for the vial, wherein the inlet is in fluid communication with the source of propellant and is directed against the in-line nasal delivery device compound and the outlet allows for delivery of the compound.

Drugs covered by this patent

dihydroergotamine-mesylate (DIHYDROERGOTAMINE MESYLATE)

Patent Metadata

Patent number: US11266799
Jurisdiction: US
Classification: Formulation
Expires: 2036-11-05
Drug substance claim: No
Drug product claim: Yes
Assignee: Impel Neuropharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.